All Stories

  1. Editorial. CCCB: The journal at age 5
  2. Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia
  3. Introduction to the special issue on brain health
  4. What will it take to achieve brain health globally?
  5. One-health approach to canine cognitive decline: Dogs Overcoming Geriatric Memory and Aging Initiative for early detection of cognitive decline
  6. PDE5 inhibitor drugs for use in dementia
  7. Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective
  8. ER stress induced immunopathology involving complement in CADASIL: implications for therapeutics
  9. A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia
  10. Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial
  11. Vascular Collagen Type-IV in Hypertension and Cerebral Small Vessel Disease
  12. Correction to: Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage
  13. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment
  14. Vasculocentric Axonal NfH in Small Vessel Disease
  15. Test–retest reliability of arterial spin labelling for cerebral blood flow in older adults with small vessel disease
  16. Vascular cognitive impairment and dementia: An early career researcher perspective
  17. What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
  18. Experimental models in VCID: What are we aiming for?
  19. The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?
  20. Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage
  21. EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel
  22. Cerebral amyloid angiopathy distribution in older people: A cautionary note
  23. Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors
  24. An introduction to therapeutic approaches to vascular cognitive impairment
  25. Strokectomy for malignant middle cerebral artery infarction: experience and meta-analysis of current evidence
  26. Association of White Matter Hyperintensities and Cardiovascular Disease
  27. UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings
  28. Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA)
  29. Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review
  30. Cell Senescence and Cerebral Small Vessel Disease in the Brains of People Aged 80 Years and Older
  31. Rapid neuroinflammatory changes in human acute intracerebral hemorrhage
  32. White matter lesions in cerebral small vessel disease
  33. WM1-4 Decompressive craniectomy versus strokectomy for malignant middle cerebral artery (MCA) infarction
  34. P112 Management and outcome of subarachnoid haemorrhage (SAH) in older people: a centre series
  35. P117 Predictive factors of outcome in poor grade subarachnoid haemorrhage (SAH)
  36. WP1-23 Vascular collagen 4A1 in subcortical white matter of older people and primates
  37. Small‐Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions
  38. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
  39. The cGMP-Degrading Enzyme Phosphodiesterase-5 (PDE5) in Cerebral Small Arteries of Older People
  40. Lesional and perilesional tissue characterization by automated image processing in a novel gyrencephalic animal model of peracute intracerebral hemorrhage
  41. Post-trial follow-up methodology in large randomised controlled trials: a systematic review
  42. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology
  43. A common drug turns on a protein enzyme that reduces stroke-like brain damage
  44. The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
  45. Neuropathology of White Matter Lesions, Blood–Brain Barrier Dysfunction, and Dementia
  46. Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies
  47. Super-resolution imaging of subcortical white matter using stochastic optical reconstruction microscopy (STORM) and super-resolution optical fluctuation imaging (SOFI)
  48. [P4-129]: A VASCULOCENTRIC PATTERN OF AXONAL DAMAGE AND NEUROFILAMENT PHOSPHORYLATION IN SUBCORTICAL WHITE MATTER OF OLDER PEOPLE
  49. Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS): study protocol for a randomised controlled trial
  50. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment
  51. Effect of phosphodiesterase-5 inhibitors on cerebral blood flow in human beings: a systematic review
  52. Translational models for vascular cognitive impairment: a review including larger species
  53. A dysfunctional blood–brain barrier and cerebral small vessel disease
  54. Post-mortem assessment in vascular dementia: advances and aspirations
  55. Vascular Contributions to Cognitive Impairment and Dementia
  56. F3-01-03: Blood-Brain Barrier Dysfunction, Small Vessel Disease and Dementia: Studies in Human Brain Tissue
  57. P2-071: Super Resolution Microscopy of Intact Brain White Matter
  58. Age-dependent expression of VEGFR2 in deep brain arteries in small vessel disease, CADASIL, and healthy brains
  59. Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID)
  60. Catecholamine-Based Treatment in AD Patients: Expectations and Delusions
  61. Endothelial Cells and Human Cerebral Small Vessel Disease
  62. Blood-Brain Barrier Dysfunction and Cerebral Small Vessel Disease (Arteriolosclerosis) in Brains of Older People
  63. P4-259: PHOSPHODIESTERASE 5 (PDE5) AS A POTENTIAL THERAPEUTIC TARGET IN SMALL ARTERIES OF AGED HUMAN BRAINS
  64. The cell survival kinase SGK1 and its targets FOXO3a and NDRG1 in aged human brain
  65. Transgene Delivery to Endothelial Cultures Derived from Porcine Carotid Artery Ex Vivo
  66. Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis
  67. An MRI-Histological Study of White Matter in Stroke-Free SHRSP
  68. Pre-clinical models of human cerebral small vessel disease: Utility for clinical application
  69. Whole-Cell Patch-Clamp Recording of Voltage-Sensitive Ca2+ Channel Currents in Single Cells: Heterologous Expression Systems and Neurones
  70. Neuropathologic evidence of endothelial changes in cerebral small vessel disease
  71. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review
  72. Pharmacology of capsaicin-, anandamide-, and N -arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population
  73. Death-associated protein kinase (DAPK1) in cerebral cortex of late-onset Alzheimer's disease patients and aged controls
  74. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia
  75. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease
  76. Doin vivoExperimental Models Reflect Human Cerebral Small Vessel Disease? a Systematic Review
  77. The Nitrone Disodium 2,4-Sulphophenyl-N-Tert-Butylnitrone is Without Cytoprotective Effect on Sodium Nitroprusside-Induced Cell Death in N1E-115 Neuroblastoma Cells in vitro
  78. Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca2+]i, initiates neurotransmitter release and promotes delayed cell death
  79. Glutamate receptor-mediated inhibition of l-glutamate efflux from cerebral cortex in vitro
  80. Sipatrigine (BW 619C89) is a Neuroprotective Agent and a Sodium Channel and Calcium Channel Inhibitor
  81. Deep brain stimulation in Parkinson’s disease patients: biochemical evidence
  82. Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus
  83. Expression of Cellular FLICE Inhibitory Proteins (cFLIP) in Normal and Traumatic Murine and Human Cerebral Cortex
  84. Supercritical carbon dioxide foaming of elastomer/heterocyclic methacrylate blends as scaffolds for tissue engineering
  85. Subthalamic stimulation activates internal pallidus: Evidence from cGMP microdialysis in PD patients
  86. Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
  87. Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents
  88. Actions of the sodium channel inhibitor 202W92 on rat midbrain dopaminergic neurons
  89. Pharmacology of ischemia-induced glutamate efflux from rat cerebral cortex in vitro
  90. Electrophysiological actions of γ-aminobutyric acid and clomethiazole on recombinant GABAA receptors
  91. Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons
  92. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92
  93. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro
  94. The interaction of AR-A008055 and its enantiomers with the GABAA receptor complex and their sedative, muscle relaxant and anticonvulsant activity
  95. Effects of extracellular pH on the interaction of sipatrigine and lamotrigine with high-voltage-activated (HVA) calcium channels in dissociated neurones of rat cortex
  96. Nociceptin/orphanin FQ inhibits ischaemiainduced glutamate efflux from rat cerebrocortical slices
  97. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke
  98. On the regulation of ischaemia-induced glutamate efflux from rat cortex by GABA;in vitrostudies with GABA, clomethiazole and pentobarbitone
  99. Inhibition of recombinant low-voltage-activated Ca2+ channels by the neuroprotective agent BW619C89 (Sipatrigine)
  100. Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?
  101. Electrophysiology of Sipatrigine: A Lamotrigine Derivative Exhibiting Neuroprotective Effects
  102. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89
  103. Acute effects of interleukin-1β on noradrenaline release from the human neuroblastoma cell line SH-SY5Y
  104. Inhibition of human N-type voltage-gated Ca2+ channels by the neuroprotective agent BW619C89
  105. Hypotonicity-induced anion fluxes in cells expressing the multidrug-resistance-associated protein, MRP
  106. Origins of open-channel noise in the large potassium channel of sarcoplasmic reticulum.
  107. Identification and electrophysiology of isolated pars compacta neurons from guinea-pig substantia nigra
  108. Tolbutamide reverses membrane hyperpolarisation induced by activation of D2 receptors and GABAB receptors in isolated substantia nigra neurones
  109. Gramicidin-mediated currents at very low permeant ion concentrations
  110. Effects of double-layer polarization on ion transport
  111. Whole-Cell Patch Clamp Recording of Voltage-Sensitive Ca2+ Channel Currents: Heterologous Expression Systems and Dissociated Brain Neurons
  112. Experimental animal models of cerebral small vessel disease